Clinical trial
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
NCT00105183 · Neovii Biotech, Industry · Completed
Key facts
| NCT number | NCT00105183 |
|---|---|
| Title | EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection |
| Official title | A Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of an Anti-human-T-lymphocyte Immune Globulin (EZ-2053) in the Prophylaxis of Acute Pulmonary Allograft Rejection in Adult Recipients of Primary Pulmonary Allograft(s) |
| Lead sponsor | Neovii Biotech, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease |
| Intervention type | Biological |
| Interventions | Placebo, EZ-2053, EZ-2053 5mg/kg |
| Enrollment | 223 |
| Start date | Jan 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2011 |
| First posted | Mar 9, 2005 |
| Last update posted | Jun 11, 2012 |
| Countries | Australia, Austria, Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: